Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation.
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision nanomedicines enabled by our hydroxyl dendrimer (HD) technology to treat unmet medical needs in ophthalmology, neurology, and inflammatory diseases. Our precision nanomedicines are selectively taken up only by inflamed tissues, allowing us to treat disease with unprecedented precision.
We have designed a potent anti-angiogenic nanomedicine that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages, and retinal pigment epithelial cells in the eye
Company to present 40-week topline results from the Phase 2 study of migaldendranib (MGB), a first-in-class subcutaneous nanomedicine, being developed for the treatment of DME
FDA agrees with Phase 2b/3 clinical design, including primary endpoint and development approach, providing clear regulatory pathway to conduct two studies under single protocol Dempsey
Migaldendranib (MGB), a subcutaneous nanomedicine, represents potential paradigm shift from frequent intravitreal injections REDWOOD CITY, Calif., October 8, 2025 — Ashvattha Therapeutics (“Ashvattha”), a